Recent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthood
DOI:
https://doi.org/10.20882/adicciones.169Keywords:
Naltrexone, implant, heroin, addiction, methadone, opiate, overdose, hepatotoxicity, AustraliaAbstract
Implants and depot injections (DI) of naltrexone (NTX) have undergone considerable development since the first commercially available implants appeared in the mid-1990s. In particular, long-acting implants that can deliver relapse-preventing serum NTX levels for around six months have now been subjected to classic randomised controlled trials that have given positive and generally significant results when compared with oral NTX and placebo implants, or with standard post-detoxification care. They also provide lower serum levels that can prevent opiate overdose for several additional months and 3-year mortality rates are similar to those of methadone maintenance treatment (MMT). At least 18 months of antagonist-assisted abstinence may be desirable to normalise new, opiatefree cognitive-behavioural habits and extinguish old, maladaptive ones. We discuss ideological antagonisms between protagonists of MMT and of NTX implants, notably in Australia, but we argue that both treatments can and should co-exist. The main obstacle to the expansion of longacting implant treatment is not the lack of an evidential or theoretical base but the lack of a licensed product. NTX appears to block all opiates if serum levels are adequate and we stress its apparent lack of clinically significant hepatotoxicity. Some patients may need above-average serum levels and occasionally, habitual injectors continue to inject opiates despite experiencing no opiate effects.References
Brewer C, Streel E. Naltrexone implants: a real therapeutic advance, both behavioural and pharmacological. (Implantes de naltrexone: un avance terpaeutico, tanto comportamental como farmacologico.) Adicciones 2003; 15(4) 299-308
Carreno JE, Alvarez CE, Narciso GI, Bascaran MT, Diaz M, Bobes J. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology. 2003;8(4):429-38.
Jonsen J, Mørland G. Depot preparations of disulfiram:
experimental and clinical results. Acta Psychiatrica Scandinavica 1992;86:27-30.
Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O’Brien CP, Woody GE. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. E. J Subst Abuse Treat. 2006 Dec;31(4):319-28.
Partecke L. Personal communication.
Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical
outcomes in treating heroin dependence: controlled trialof oral or implant naltrexone. Arch Gen Psychiatry, 2009 Oct: 66(10):1108-15
Arnold-Reed DE, Hulse GK. A comparison of rapid (opioid) detoxification with clonidine-assisted detoxification for heroin-dependent persons. Journal of Opioid Management. 2005;1(1):17-23.
Strang J, Mc Cambridge J, Best D, Beswick T, Bearn J, Rees S, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. British Medical Journal. 2003;326:959-60.
Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Brit J Psychiat. 2009;194:541-6.
Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al Retention in Naltrexone implant treatment for opioid dependence. Drug Alc Depend 2010 in press
Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone
Implants Compared to Methadone: Outcomes Six Months after Prison Release. Eur Addict Res. 2010 Apr 26;16(3):139-145.
Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release
naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006140.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP. Injectable, sustainedrelease naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006 Feb;63(2):210-8.
Krupitsky EM, Blokhina EA.Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry. 2010 Mar 10.
Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with a drug-free communitybased programme: the first cohort. Journal of Clinical Forensic Medicine. 1996;3:87-92.
Cornish J, Metzger D, Woody G, Wilson D, Mclellan T, Vandergrift B, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. Substance Abuse Treatment. 1997;14(6):529-34.
Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug and Alcohol Review. 2000;19:41-8.
Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol. 2002.7:
Krupitzky E, Burakov A, M. V. Tsoy M, Egorova V, Slavina T, Grinenko A, Zvartau E, Woody G. Overcoming opioid blockade from depot naltrexone (Prodetoxon®) Addiction, 2007. 102 (7) July, 1164-1165
Hulse G. Tait R. A pilot study to assess the impact of naltrexone
implant on accidental opiate overdose in ‘high risk’ adolescent heroin users. Addiction Biology 2003; 8 (3) 337-342.
Hulse G, Tait R, Comer S. et al. Reducing hospital presentations in opioid overdose in patients treated with sustained release naltrexone implants. Drug Alc Depend. 2005; 79: 351-357
Brewer C, Streel E. Current issues in the use of opioid antagonists. In: (Eds: Reginald L. Dean III, Edward J. Bilsky and S. Stevens Negus III.) Opioid Receptors and Antagonists: From Bench to Clinic. Contemporary Neuroscience series. Wiley. NY. 2009
Hulse GK, Ngo HT, Tait RJ. Risk Factors for Craving and Relapse in Heroin Users Treated with Oral or Implant Naltrexone. Biol Psychiatry. 2010 In press.
